Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study
研究概览
地位
详细说明
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:ou bai, MD/PHD
- 电话号码:13039046656
- 邮箱:oubai16@163.com
学习地点
-
-
Jilin
-
Changchun、Jilin、中国、130021
- The First Bethune Hospital of Jilin University
-
接触:
- ou bai, MD/PHD
- 电话号码:13039046656
- 邮箱:oubai16@163.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patients of any gender, aged ≥18 years;
- Pathologically, NGS, and imaging confirmed diagnosis of MCD subtype DLBCL (including IP-LBCLs);
- No prior treatment history;
- Serum creatinine ≤2 times the upper limit of normal or eGFR ≥40 ml/min;
- Bilirubin <1.5 times the upper limit of normal;
- Understand and voluntarily sign a written informed consent form.
Exclusion Criteria:
- Pregnant or lactating women and women of childbearing age who are unwilling to use contraception;
- Patients with a history of stroke or bleeding within the past 6 months;
- Patients requiring treatment with strong CYP3A inhibitors;
- Patients with comorbid autoimmune deficiency diseases or active hepatitis virus infection;
- Patients with a history of organ transplantation;
- Patients with a history of or concurrent other malignant tumors.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Orelabrutinib Combined with chemotherapy followed by monotherapy in ND MCD subtype DLBCL
For MCD subtype DLBCL (including IP-LBCLs) that have undergone two cycles of induction therapy, combine orelabrutinib treatment starting from the third cycle. For patients with poor prognostic factors (meeting one of the following: Ann Arbor stage III/IV; IPI score 3-5; aaIPI score 2-3; high-intermediate or high-risk group per MSKCC and/or IELSG criteria), continue with two additional cycles of orelabrutinib-combined induction therapy, followed by orelabrutinib monotherapy maintenance for 2 years or until disease progression or intolerable toxicity. For patients without poor prognostic factors, administer orelabrutinib monotherapy maintenance for 1 year or until disease progression or intolerable toxicity. |
R-CHOP Regimen Rituximab: 375 mg/m², Day 0 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Vincristine: 1.4 mg/m², Day 1 (maximum single dose: 2 mg) Prednisone: 100 mg, Days 1-5 Orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
POLA-R-CHP+orelabrutinib Rituximab: 375 mg/m², Day 1 Vepoliximab: 1.8 mg/kg, Day 1 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Prednisone: 100 mg, Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
R-miniCHOP Regimen Rituximab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
Zuberitamab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
POLA-Hi-CHP+orelabrutinib Zuberitamab: 375 mg/m², Day 1 Vepoliximab: 1.8 mg/kg, Day 1 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Prednisone: 100 mg, Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
Hi-miniCHOP Regimen Zuberitamab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
RMTO Regimen Rituximab: 375 mg/m², Day 1 Methotrexate: 3.5 g/m², Day 2 Thiotepa 30 mg/m² Day 4 Orelabrutinib: 150 mg, Days 1-21 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
HiMTO Regimen Zuberitamab: 375 mg/m², Day 1 Methotrexate: 3.5 g/m², Day 2 Thiotepa 30 mg/m² Day 4 Orelabrutinib: 150 mg, Days 1-21 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
Pola-R-miniCHP Regimen Polatuzumab vedotin: 1.8 mg/kg IV, Day 1 Rituximab: 375 mg/m² IV, Day 1 Cyclophosphamide: 400 mg/m² IV, Day 1 Doxorubicin: 25 mg/m² IV, Day 1 Prednisone: 40 mg/m² PO, Days 1-5 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
Pola-Hi-miniCHP Regimen (21-day cycle, up to 6 cycles) Polatuzumab vedotin: 1.8 mg/kg IV, Day 1 Zuberitamab: 375 mg/m² IV, Day 1 Cyclophosphamide: 400 mg/m² IV, Day 1 Doxorubicin: 25 mg/m² IV, Day 1 Prednisone: 40 mg/m² PO, Days 1-5 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2year PFS
大体时间:From the start of treatment up to 2 years
|
The percentage of subjects who had not experienced disease progression or all-cause death at 24 months from first dose, relative to the total enrolled population.
|
From the start of treatment up to 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ORR
大体时间:From the start of treatment up to 2 years
|
The proportion of patients who achieved a PR or better response at the end of therapy
|
From the start of treatment up to 2 years
|
|
CRR
大体时间:From the start of treatment up to 2 years
|
Proportion of patients achieving CR at the end of treatment
|
From the start of treatment up to 2 years
|
|
OS
大体时间:From the start of treatment up to 2 years
|
Time from treatment initiation to death from any cause
|
From the start of treatment up to 2 years
|
|
AEs
大体时间:From the start of treatment up to 2 years
|
All adverse medical events that occurred after the initiation of treatment
|
From the start of treatment up to 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 肿瘤
- 组织学类型的肿瘤
- 淋巴系统疾病
- 组织细胞疾病,恶性
- 组织细胞增多症
- 半身和淋巴疾病
- 树突状细胞肉瘤,指叉型
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 生物碱
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 吲哚
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 翼
- 翼状
- 妊娠二培养子
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 氨基翅目
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 抗体,单克隆,鼠的衍生
- Daunorubicin
- 三乙基磷酰胺
- 阿祖里丁
- Azirines
- 利妥昔单抗
- 甲氨蝶呤
- 强的松
- 环磷酰胺
- 阿霉素
- 长春新碱
- 噻替派
- polatuzumab vedotin
- Olelabrutinib
其他研究编号
- 25K405-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.